Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

42 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Proliferative activity in human breast cancer: Ki-67 automated evaluation and the influence of different Ki-67 equivalent antibodies.
Fasanella S, Leonardi E, Cantaloni C, Eccher C, Bazzanella I, Aldovini D, Bragantini E, Morelli L, Cuorvo LV, Ferro A, Gasperetti F, Berlanda G, Dalla Palma P, Barbareschi M. Fasanella S, et al. Among authors: aldovini d. Diagn Pathol. 2011 Mar 30;6 Suppl 1(Suppl 1):S7. doi: 10.1186/1746-1596-6-S1-S7. Diagn Pathol. 2011. PMID: 21489202 Free PMC article.
Diagnostic value of automated Her2 evaluation in breast cancer: a study on 272 equivocal (score 2+) Her2 immunoreactive cases using an FDA approved system.
Cantaloni C, Tonini R E, Eccher C, Morelli L, Leonardi E, Bragantini E, Aldovini D, Fasanella S, Ferro A, Cazzolli D, Berlanda G, Dalla Palma P, Barbareschi M. Cantaloni C, et al. Among authors: aldovini d. Appl Immunohistochem Mol Morphol. 2011 Jul;19(4):306-12. doi: 10.1097/PAI.0b013e318205b03a. Appl Immunohistochem Mol Morphol. 2011. PMID: 21293256
Frequency of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from Trentino, North East Italy.
Giuliani S, Leonardi E, Aldovini D, Bernardi D, Pellegrini M, Soli F, Ferro A, Dalla Palma P, Decarli N, Barbareschi M. Giuliani S, et al. Among authors: aldovini d. Pathologica. 2012 Jun;104(3):93-7. Pathologica. 2012. PMID: 22931039
The reproducibility of CIN diagnoses among different pathologists: data from histology reviews from a multicenter randomized study.
Dalla Palma P, Giorgi Rossi P, Collina G, Buccoliero AM, Ghiringhello B, Gilioli E, Onnis GL, Aldovini D, Galanti G, Casadei G, Aldi M, Gomes VV, Giubilato P, Ronco G; NTCC Pathology Group. Dalla Palma P, et al. Among authors: aldovini d. Am J Clin Pathol. 2009 Jul;132(1):125-32. doi: 10.1309/AJCPBRK7D1YIUWFP. Am J Clin Pathol. 2009. PMID: 19864243 Clinical Trial.
[Tissue microarrays in oncology].
Barbareschi M, Togni R, Aldovini D, Peterlini G, Dal Santo M, Sagramoso C, Dalla Palma P, Lucenti A, Caffo O, Galligioni E, Demichelis F, Sboner A, Dell'Anna R, Di Vizio D, Insabato L, Pettinato G, Mazzoleni G, Macrì E, Doglioni C. Barbareschi M, et al. Among authors: aldovini d. Pathologica. 2003 Oct;95(5):265-6. Pathologica. 2003. PMID: 14989013 Italian. No abstract available.
Prognostic value of estrogen receptor status can be improved by combined evaluation of p53, Bcl2 and PgR expression: an immunohistochemical study on breast carcinoma with long-term follow-up.
Mauri FA, Maisonneuve P, Caffo O, Veronese S, Aldovini D, Ferrero S, Cozzaglio F, Dalla Palma P, Galligioni E, Barbareschi M. Mauri FA, et al. Among authors: aldovini d. Int J Oncol. 1999 Dec;15(6):1137-47. doi: 10.3892/ijo.15.6.1137. Int J Oncol. 1999. PMID: 10568820
AgNOR distribution in serous tumours of the ovary.
Mauri FA, Scampini S, Aldovini D, Ferrero S, Barbareschi M, Dalla Palma P. Mauri FA, et al. Among authors: aldovini d. Pathologica. 1990 Sep-Oct;82(1081):487-92. Pathologica. 1990. PMID: 1706828
42 results